Contact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
Dr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses recent developments in bladder cancer treatment, including immune checkpoint inhibitors.
Continue readingDr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses how antibody-drug conjugates are used in the treatment of advanced urothelial cancer.
Continue reading
Dr. Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab.
Continue readingThe Academic Urology Research Investigators Consortium met for an initial Investigator’s Meeting during the recent GU-ASCO 2023 in San Francisco to explore new studies for the coming year. The group’s primary focus is to partner with pharmaceutical companies looking to explore novel genitourinary oncology trials.
Continue reading
AURIC Director Thomas Flaig, MD, of the University of Colorado Anschutz Medical Campus in Aurora, Colorado, provides an overview of the management of toxicities with novel systemic therapies in patients with urothelial carcinoma (UC), highlighting the use of antibody-drug conjugates in advanced disease.
Continue reading